KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Expenses (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Operating Expenses for 11 consecutive years, with $155.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 55.2% to $155.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $668.1 million through Dec 2025, up 32.59% year-over-year, with the annual reading at $668.1 million for FY2025, 32.59% up from the prior year.
  • Operating Expenses hit $155.6 million in Q4 2025 for CRISPR Therapeutics AG, up from $132.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $230.2 million in Q2 2025 to a low of $100.3 million in Q4 2024.
  • Historically, Operating Expenses has averaged $149.1 million across 5 years, with a median of $145.2 million in 2024.
  • Biggest five-year swings in Operating Expenses: surged 71.04% in 2021 and later dropped 27.44% in 2023.
  • Year by year, Operating Expenses stood at $158.6 million in 2021, then decreased by 17.06% to $131.5 million in 2022, then grew by 0.06% to $131.6 million in 2023, then fell by 23.81% to $100.3 million in 2024, then surged by 55.2% to $155.6 million in 2025.
  • Business Quant data shows Operating Expenses for CRSP at $155.6 million in Q4 2025, $132.9 million in Q3 2025, and $230.2 million in Q2 2025.